transhiatal (THO) and 2-stage (2-ST) resections are routinely practised in our unit, largely according to individual surgeon preference.
Methods A prospectively collected database containing 550 consecutive resections was available for analysis. All other variables (Investigation, MDT decision making and ITU input) were consistent within the unit.
Results Between 2000 and 2010, 267 patients underwent THO and 283 had 2-ST oesophagectomy. Demographics showed equal characteristics between the groups with a median age of 65 years old and a predominantly male population. Adenocarcinomas made up 79% of resections. 330 (60%) patients underwent neo-adjuvant chemotherapy. 58% were pre-operatively staged as having stage 3 disease. In-hospital mortality was 1.1% (THO) vs 1.5% (2-ST). Hospital stay was similar between the two groups (median 14 days vs 15 days). Median survival on Kaplan–Meier analysis was 49 months for THO vs 34 months for 2-ST ($p<0.0005$). Further analysis of the 2-ST procedures showed median survival of 40 months, 29 months and 23 months for laparoscopic assisted, left thoraco-abdominal and ivor-lewis resections respectively.
Conclusion Only one randomised trial has ever compared the two operative approaches, demonstrating no survival advantage for more radical 2-Stage surgery. Quality of life data may support transhiatal resections. Our data suggests that transhiatal resections carry a low post-operative mortality with good long term survival rates that are at least comparable to 2-Stage procedures. Transhiatal oesophagectomy is a viable alternative in the treatment of oesophageal cancer.

Competing interests None declared.

PTU-169 GIANT HIATUS HERNIA REPAIR: A SINGLE-CENTRE EXPERIENCE OF THE CRURASOFT® (BARD) COMPOSITE MESH

doi:10.1136/gutjnl-2012-302514c.169

A C Katz-Summercorn,* A C Hindmarsh, R H Hardwick, P M Safranek. *Cambridge Oesophago-gastric Centre, Addenbrooke's Hospital, Cambridge, UK*

Introduction Use of prosthetic mesh is advocated in giant hiatus hernia repair to reduce the chance of recurrence. However, complications related to the use of mesh at the oesophageal hiatus have been reported. Composite meshes have been developed which have a lower adhesive potential and may reduce complication rates. We report the outcome of a large case series of patients undergoing hiatus hernia repair using the composite Crurasoft® (BARD) mesh.
Methods A retrospective study was performed of all patients who had undergone primary or recurrent hiatus hernia repair using Crurasoft® (BARD) mesh in a single tertiary referral centre. Patient demographics, pre-operative investigations, operation and follow-up details were recorded.
Results Over a 6-year period 53 patients underwent laparoscopic hiatus hernia repair using Crurasoft® (BARD) mesh, of which 36 patients had a primary giant hiatus hernia repair. A concurrent anti-reflux procedure was performed in 44 patients. There were three conversions to open operation, two in patients undergoing primary repair due to difficulties reducing the stomach, and one in a patient undergoing surgery for recurrence due to adhesions. The median time for follow-up was 45 months (range 8–94). Significant complications included dysphagia in 12 (22.6%) patients, which was due to an oesophageal stricture in 2 (3.8%) patients. Mesh erosion into the oesophagus occurred in 2 (3.8%) patients, and 12 (22.6%) patients developed a symptomatic recurrence. Reoperation within 30 days of initial surgery was required in 5 (9.4%) patients and was due to an early recurrence in 3 (5.7%) patients. There were no mortalities.
Conclusion The composite Crurasoft® (BARD) mesh can successfully be used in giant hiatus hernia repair. However, this mesh does not prevent significant mesh related oesophageal complications and is associated with a high recurrence rate.

Competing interests None declared.

PTU-170 A COMPARISON OF THE EARLY QUALITY OF LIFE OUTCOMES BETWEEN OPEN AND LAPAROSCOPIC OESOPHAGOGASTRIC RESECTIONAL SURGERY

doi:10.1136/gutjnl-2012-302514c.170

A Menon,* S Tolofari, B Knight, J Stockton, J Vickers, L Formela, K Akhtar, S Senapati. *Oesophagogastric Surgery, Salford Royal Hospital, Salford, UK*

Introduction There is a paucity of data directly comparing health related quality of life (HRQL) between laparoscopic and open oesophagogastric resections. This study aims to evaluate differences between these groups in the early postoperative period.
Methods The European Organisation for Research and Treatment Quality of Life Questionnaire Core 30 (EORTC QLQ-30) was administered to 34 patients preoperatively, and 1 month following laparoscopic gastrectomy (n=6), open gastrectomy (n=8), open two-phase oesophagectomy (n=7), and two-phase oesophagectomy with laparoscopic gastric mobilisation (n=13). Mann–Whitney U tests were used to compare HRQL between open and laparoscopic resections, and related sample Wilcoxon signed rank tests were used to compare 1 month and preoperative HRQL.
Results There was no significant difference in median preoperative functional and global HRQL between both the open and laparoscopic gastrectomy groups (10 vs 11, p=0.41; 11 vs 11, p=1.00), and between the open and laparoscopic-assisted oesophagectomy groups (18 vs 11, p=0.18; 10 vs 11, p=0.70). Functional HRQL worsened significantly at 1 month with both open gastrectomy (18 vs 10, p=0.01) and open oesophagectomy (18 vs 11, p=0.02), but not with laparoscopic gastrectomy (15 vs 11, p=0.11) and laparoscopic assisted-oesophagectomy (15 vs 18, p=0.81). Global HRQL was significantly worse at 1 month with open gastrectomy (7 vs 11, p=0.04), but not in the other groups. Global HRQL was also found to be significantly higher at 1 month in the laparoscopic assisted oesophagectomy group compared with open oesophagectomy (10 vs 8, p=0.03).
Conclusion These results demonstrate significant differences in HRQL between open and laparoscopic oesophagogastric resections even at 1 month, which may indicate that the laparoscopic approach is associated with faster postoperative recovery.

Competing interests None declared.

PTU-171 OESTROGEN PLAYS A CRITICAL ROLE IN MURINE EPITHELIAL HEALING IN A BUCCAL MODEL OF REFLUX INJURY

doi:10.1136/gutjnl-2012-302514c.171

B T Theron,* N Trudgill. *Gastroenterology, Sandwell Hospital, West Bromwich, UK*

Introduction Severe oesophagitis, oesophageal adenocarcinoma (OAC) are more common in men and post-menopausal women. Female sex hormones may protect pre-menopausal women from gastro-oesophageal reflux mediated mucosal damage, delaying the onset of BO and development of OAC in women. We have demonstrated more rapid mucosal healing and less inflammatory response in females in a murine buccal model of reflux injury. We have used a model comparing intact female mice with oestrogen deprived mice (by removal of their ovaries) to determine if this effect may be oestrogen driven.

Gut: first published as 10.1136/gutjnl-2012-302514c.171 on 28 May 2012. Downloaded from http://gut.bmj.com/ on April 16, 2024 by guest. Protected by copyright.

Methods Female mice (C57 strain) were divided into three groups of 5: ovariectomised (OVX), OVX with oestrogen replacement (OVX +E) (50 μg oestradiol per day dorsal implants) and intact females. 1.5 mm buccal ulcers were induced using a punch biopsy and treated with 1 M hydrochloric acid. Wounds were harvested at day 4. Wound planimetry and immunohistochemistry for macrophages and neutrophils were compared in a blinded fashion.

Results Results: Re-epithelialisation was greatest in the intact group (mean 0.88 mm SEM ± 0.22) compared to the OVX (0.51 mm ± 0.13) or OVX+E (0.79 mm ± 0.12) groups. The difference between intact and OVX groups was statistically significant (p=0.04). Neutrophil wound infiltration (cells/wound area) was greater in the OVX group (1842±75) than the intact group (1279±169, p There was a greater number of macrophages in the OVX wounds (1556±128) than both OVX+E (984±95 (p=0.02) and the intact group (1026±91, p=0.01).

Conclusion Lack of systemic oestrogen delays mucosal healing in buccal wounds. This may explain gender differences in the oesophageal epithelial response to gastro-oesophageal reflux injury.

Competing interests None declared.

PTU-172 OESOPHAGEAL CANCER RISK: RESULTS OF A PROSPECTIVE COHORT WITH BARRETT'S OESOPHAGUS

doi:10.1136/gutjnl-2012-302514c.172

[1]B T Theron,* [1]H Padmanabhan, [1]H Aladin, [2]B T Cooper, [1]N Trudgill. [1]*Gastroenterology, Sandwell, West Bromwich, UK;* [2]*Gastroenterology, City Hospital, Birmingham, UK*

Introduction Widely varying rates of oesophageal adenocarcinoma (OAC) in patients with Barrett's oesophagus (BO) have been reported, with recent studies and meta-analyses suggesting a lower incidence, affecting the cost effectiveness of surveillance. However, advances in endoscopic therapy for dysplasia suggest surveillance should potentially be extended to more elderly patients. We have therefore examined long term outcomes in a BO cohort.

Methods BO patients with intestinal metaplasia from a prospectively maintained database (1982–2008) were analysed. Cancer registrations and causes of death from death certificates were obtained from the NHS information centre for health and social care and cross-referenced with local data. The incidence of OAC was calculated as events per 100 person years (% per year) of follow-up. Regression analysis was used to determine associations between the OAC development and age, sex, hiatus hernia, BO length, strictures and ulcers. Standardised mortality ratios were calculated using age adjusted indirect standardisation. Patients were subdivided into those suitable for surveillance and those deemed unfit due to age or comorbidity.

Results 713 (429 male, median age at diagnosis 64 years, range 30–92) BO patients were in the cohort. After a median of 11 (range 2–24) years of follow-up, 38 (27 male, median age 70 (48–90)) patients were diagnosed with OAC. The incidence of OAC was 0.5% per annum (p.a.). In patients considered suitable for surveillance, the incidence was 0.6% p.a. compared to 0.3% (p=0.06) in those not surveyed due to age or comorbidity. The rate of OAC in surveyed patients from 1982 to 1989 was 0.6% p.a., from 1990 to 1999 0.4% and from 2000 to 2008 0.5%. OAC was associated with increasing BO length (OR 1.11 (95% CI 1.01 to 1.13), p=0.03), but not with male sex (OR 1.66 (95% CI 0.8 to 3.4)), hiatus hernia (OR 1.31 (95% CI 0.68 to 2.57)), ulcer (OR 0.39, (95% CI 0.01 to 1.65)) or stricture (OR 0.97 (95% CI 0.37 to 3.1)). Standardised mortality ratios was elevated for the whole group at 181 (95% CI 162 to 181). Increasing age was associated with dying from OAC (OR 1.09 (95% CI 1.07 to 1.11) but not with the development of OAC (OR 0.99, (95% CI 0.96 to 1.01). 41% deaths in the cohort were from cardiorespiratory disease.

Conclusion The risk of OAC within this prospectively surveyed cohort was 0.5% per annum, which is higher than recent estimates. The rate of OAC in surveyed BO appears to have remained stable over the last 3 decades. Increasing length of BO is associated with a higher risk of developing OAC. BO is associated with an excess mortality risk and this is mainly related to cardiorespiratory disease.

Competing interests None declared.

PTU-173 NEUROEPITHELIAL CELL TRANSFORMING GENE 1 IN ADENOCARCINOMA OF THE OESOPHAGO-GASTRIC JUNCTION: EXPRESSION, BIOLOGY AND PROGNOSTIC SIGNIFICANCE IN A LARGE WELL CHARACTERISED COHORT

doi:10.1136/gutjnl-2012-302514c.173

[1]C Lahiff,* [2]D Murray, [2]P MacMathuna, [3]G Pidgeon, [3]J Reynolds. [1]*Gastrointestinal Unit, Mater Hospital, Dublin, Dublin 7;* [2]*Mater Hospital, Dublin, Dublin 7;* [3]*Department of Surgery, St. James's Hospital, Dublin 8, Ireland*

Introduction Neuroepithelial Transforming Gene 1 (NET1) is a protein involved in tumour invasion and metastasis and is associated with poor prognosis in a number of human cancers. We aimed to determine NET1 expression status and its prognostic significance in a large, well characterised cohort of patients with oesophageal cancer and cancer of the oesophago-gastric junction.

Methods NET1 expression was measured by immunohistochemistry in a 210 patient tissue micro-array (TMA). The TMA was constructed from bio-banked tissue using a comprehensive and prospectively maintained clinical database which includes demographic, clinical, histopathological and survival data on all patients.

Results Of 210 patients in the original cohort, 89 had a post-operative diagnosis of oesophageal adenocarcinoma and did not receive neoadjuvant chemotherapy or radiotherapy. Five patients had oesophageal adenocarcinoma, 81 had cancer of the oesophago-gastric junction and three had gastric adenocarcinoma. Of the 89 patients 51% were NET1 positive. NET1 staining was variable across tumour subtpes. Using the Siewert classification for OGJ tumours, significantly more type I tumours were NET1 positive (p=0.008) and there was significantly more Barrett's in the NET1 positive group (59% vs 30%, p=0.009). Median disease specific survival for the overall group was 37 months for NET1 negative patients compared with 23 months for NET1 positive. In patients with gastric and OGJ type III tumours, NET1 positivity was associated with worse median survival (23 vs 15 months, p=0.02). Within this subgroup (n=31), NET1 positive patients were more likely to be female (p=0.04), have advanced stage cancer (p=0.03), had a higher number of transmural cancers (p=0.006) and a significantly higher median number of positive lymph nodes (p=0.03).

Conclusion There is growing recognition of the heterogeneity of the different subtypes of OGJ tumours. While existing data shows differences in clinical and prognostic indices in these patients, there are no studies showing differences in tumour biology between OGJ sub-types. Our data suggests NET1, a known mediator of an aggressive tumour phenotype in numerous human cancers, is differentially expressed across OGJ sub-types and may be of prognostic significance in the clinical management of this disease.

Competing interests None declared.

Gut: first published as 10.1136/gutjnl-2012-302514c.171 on 28 May 2012. Downloaded from http://gut.bmj.com/ on April 16, 2024 by guest. Protected by copyright.